-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Biopharmaceutical company Boya Jiyin and Cell Ecology Haihe Laboratory recently signed a strategic cooperation R&D agreement.
Based on their respective technology and resource advantages, the two parties will jointly promote the development and transformation of hematopoietic stem cells and the implementation of gene therapy-related technologies and products, creating the original hematopoietic stem cell therapy in China.
Innovative research and clinical translation platform
.
Based on their respective technology and resource advantages, the two parties will jointly promote the development and transformation of hematopoietic stem cells and the implementation of gene therapy-related technologies and products, creating the original hematopoietic stem cell therapy in China.
Innovative research and clinical translation platform
.
The Cell Ecology Haihe Laboratory is a new R&D institution based on the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), dedicated to basic research on cell ecology, technological innovation and achievement transformation
.
The laboratory is of great strategic significance for gathering high-end innovative resources in the global cell industry, building a biomedical industry cluster that leads the high-quality development of the life and health industry, and supports a global appeal
.
.
The laboratory is of great strategic significance for gathering high-end innovative resources in the global cell industry, building a biomedical industry cluster that leads the high-quality development of the life and health industry, and supports a global appeal
.
According to the cooperation agreement, the two parties will carry out a series of research cooperation in the field of hematopoietic stem cell regeneration therapy, including developing innovative gene-modified hematopoietic stem cell therapy for specific Chinese blood genetic diseases, and exploring new hematopoietic stem cell biomarkers to optimize stem cell production quality control process
.
.
"Cell technology and cell drugs are important breakthroughs in the reform of the medical treatment model in the future.
Giving full play to the advantages of the national platform and promoting the integration of production, education and research is an important way to realize the transformation of cell technology and the implementation of products
.
" Executive Deputy Director of Cell Ecology Haihe Laboratory, China Professor Cheng Tao, director of the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), said that hematopoietic stem cells have long-term self-renewal ability and the potential to differentiate into various mature blood cells.
Solutions for a variety of diseases, including tumors , autoimmune diseases
, and inherited blood diseases .
It is believed that this cooperation can accelerate the innovation of the source technology and the transformation of achievements in the field of hematopoietic stem cells, and provide new means of safeguarding people's health
.
Giving full play to the advantages of the national platform and promoting the integration of production, education and research is an important way to realize the transformation of cell technology and the implementation of products
.
" Executive Deputy Director of Cell Ecology Haihe Laboratory, China Professor Cheng Tao, director of the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), said that hematopoietic stem cells have long-term self-renewal ability and the potential to differentiate into various mature blood cells.
Solutions for a variety of diseases, including tumors , autoimmune diseases
, and inherited blood diseases .
It is believed that this cooperation can accelerate the innovation of the source technology and the transformation of achievements in the field of hematopoietic stem cells, and provide new means of safeguarding people's health
.
In 2021, Boya Jiyin initiated a phase I multicenter clinical trial of ET-01, the first gene-edited hematopoietic stem cell therapy research product for transfusion-dependent β-thalassemia in China, and was conducted in the Hematology Hospital of the Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences).
Institute of Hematology) completed the first patient enrollment
.
At present, the clinical trial is being carried out in multiple clinical centers in Tianjin and the Guangdong-Hong Kong-Macao Greater Bay Area
.
Institute of Hematology) completed the first patient enrollment
.
At present, the clinical trial is being carried out in multiple clinical centers in Tianjin and the Guangdong-Hong Kong-Macao Greater Bay Area
.
Dr.
Wei Dong, CEO of Boya Jiyin, said that the cooperation with the Cell Ecology Haihe Laboratory will help further expand the layout and application in the field of hematopoietic stem cells.
The transformation experience in the field will bring more independent innovative treatment plans to patients in China and around the world as soon as possible
.
(Finish)
Wei Dong, CEO of Boya Jiyin, said that the cooperation with the Cell Ecology Haihe Laboratory will help further expand the layout and application in the field of hematopoietic stem cells.
The transformation experience in the field will bring more independent innovative treatment plans to patients in China and around the world as soon as possible
.
(Finish)
Biopharmaceutical company Boya Jiyin and Cell Ecology Haihe Laboratory recently signed a strategic cooperation R&D agreement.
Based on their respective technology and resource advantages, the two parties will jointly promote the development and transformation of hematopoietic stem cells and the implementation of gene therapy-related technologies and products, creating the original hematopoietic stem cell therapy in China.
Innovative research and clinical translation platform
.
Based on their respective technology and resource advantages, the two parties will jointly promote the development and transformation of hematopoietic stem cells and the implementation of gene therapy-related technologies and products, creating the original hematopoietic stem cell therapy in China.
Innovative research and clinical translation platform
.
The Cell Ecology Haihe Laboratory is a new R&D institution based on the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), dedicated to basic research on cell ecology, technological innovation and achievement transformation
.
The laboratory is of great strategic significance for gathering high-end innovative resources in the global cell industry, building a biomedical industry cluster that leads the high-quality development of the life and health industry, and supports a global appeal
.
.
The laboratory is of great strategic significance for gathering high-end innovative resources in the global cell industry, building a biomedical industry cluster that leads the high-quality development of the life and health industry, and supports a global appeal
.
According to the cooperation agreement, the two parties will carry out a series of research cooperation in the field of hematopoietic stem cell regeneration therapy, including developing innovative gene-modified hematopoietic stem cell therapy for specific Chinese blood genetic diseases, and exploring new hematopoietic stem cell biomarkers to optimize stem cell production quality control process
.
.
"Cell technology and cell drugs are important breakthroughs in the reform of the medical treatment model in the future.
Giving full play to the advantages of the national platform and promoting the integration of production, education and research is an important way to realize the transformation of cell technology and the implementation of products
.
" Executive Deputy Director of Cell Ecology Haihe Laboratory, China Professor Cheng Tao, director of the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), said that hematopoietic stem cells have long-term self-renewal ability and the potential to differentiate into various mature blood cells.
Solutions for a variety of diseases, including tumors , autoimmune diseases
, and inherited blood diseases .
It is believed that this cooperation can accelerate the innovation of the source technology and the transformation of achievements in the field of hematopoietic stem cells, and provide new means of safeguarding people's health
.
Giving full play to the advantages of the national platform and promoting the integration of production, education and research is an important way to realize the transformation of cell technology and the implementation of products
.
" Executive Deputy Director of Cell Ecology Haihe Laboratory, China Professor Cheng Tao, director of the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), said that hematopoietic stem cells have long-term self-renewal ability and the potential to differentiate into various mature blood cells.
Solutions for a variety of diseases, including tumors , autoimmune diseases
, and inherited blood diseases .
It is believed that this cooperation can accelerate the innovation of the source technology and the transformation of achievements in the field of hematopoietic stem cells, and provide new means of safeguarding people's health
.
In 2021, Boya Jiyin initiated a phase I multicenter clinical trial of ET-01, the first gene-edited hematopoietic stem cell therapy research product for transfusion-dependent β-thalassemia in China, and was conducted in the Hematology Hospital of the Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences).
Institute of Hematology) completed the first patient enrollment
.
At present, the clinical trial is being carried out in multiple clinical centers in Tianjin and the Guangdong-Hong Kong-Macao Greater Bay Area
.
Institute of Hematology) completed the first patient enrollment
.
At present, the clinical trial is being carried out in multiple clinical centers in Tianjin and the Guangdong-Hong Kong-Macao Greater Bay Area
.
Dr.
Wei Dong, CEO of Boya Jiyin, said that the cooperation with the Cell Ecology Haihe Laboratory will help further expand the layout and application in the field of hematopoietic stem cells.
The transformation experience in the field will bring more independent innovative treatment plans to patients in China and around the world as soon as possible
.
(Finish)
Wei Dong, CEO of Boya Jiyin, said that the cooperation with the Cell Ecology Haihe Laboratory will help further expand the layout and application in the field of hematopoietic stem cells.
The transformation experience in the field will bring more independent innovative treatment plans to patients in China and around the world as soon as possible
.
(Finish)
Biopharmaceutical company Boya Jiyin and Cell Ecology Haihe Laboratory recently signed a strategic cooperation R&D agreement.
Based on their respective technology and resource advantages, the two parties will jointly promote the development and transformation of hematopoietic stem cells and the implementation of gene therapy-related technologies and products, creating the original hematopoietic stem cell therapy in China.
Innovative research and clinical translation platform
.
Based on their respective technology and resource advantages, the two parties will jointly promote the development and transformation of hematopoietic stem cells and the implementation of gene therapy-related technologies and products, creating the original hematopoietic stem cell therapy in China.
Innovative research and clinical translation platform
.
The Cell Ecology Haihe Laboratory is a new R&D institution based on the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), dedicated to basic research on cell ecology, technological innovation and achievement transformation
.
The laboratory is of great strategic significance for gathering high-end innovative resources in the global cell industry, building a biomedical industry cluster that leads the high-quality development of the life and health industry, and supports a global appeal
.
medicine medicine medicine.
The laboratory is of great strategic significance for gathering high-end innovative resources in the global cell industry, building a biomedical industry cluster that leads the high-quality development of the life and health industry, and supports a global appeal
.
According to the cooperation agreement, the two parties will carry out a series of research cooperation in the field of hematopoietic stem cell regeneration therapy, including developing innovative gene-modified hematopoietic stem cell therapy for specific Chinese blood genetic diseases, and exploring new hematopoietic stem cell biomarkers to optimize stem cell production quality control process
.
.
"Cell technology and cell drugs are important breakthroughs in the reform of the medical treatment model in the future.
Giving full play to the advantages of the national platform and promoting the integration of production, education and research is an important way to realize the transformation of cell technology and the implementation of products
.
" Executive Deputy Director of Cell Ecology Haihe Laboratory, China Professor Cheng Tao, director of the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), said that hematopoietic stem cells have long-term self-renewal ability and the potential to differentiate into various mature blood cells.
Solutions for a variety of diseases, including tumors , autoimmune diseases
, and inherited blood diseases .
It is believed that this cooperation can accelerate the innovation of the source technology and the transformation of achievements in the field of hematopoietic stem cells, and provide new means of safeguarding people's health
.
hospital hospital hospital tumor tumor tumor disease disease disease health health _Giving full play to the advantages of the national platform and promoting the integration of production, education and research is an important way to realize the transformation of cell technology and the implementation of products
.
" Executive Deputy Director of Cell Ecology Haihe Laboratory, China Professor Cheng Tao, director of the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), said that hematopoietic stem cells have long-term self-renewal ability and the potential to differentiate into various mature blood cells.
Solutions for a variety of diseases, including tumors , autoimmune diseases
, and inherited blood diseases .
It is believed that this cooperation can accelerate the innovation of the source technology and the transformation of achievements in the field of hematopoietic stem cells, and provide new means of safeguarding people's health
.
In 2021, Boya Jiyin initiated a phase I multicenter clinical trial of ET-01, the first gene-edited hematopoietic stem cell therapy research product for transfusion-dependent β-thalassemia in China, and was conducted in the Hematology Hospital of the Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences).
Institute of Hematology) completed the first patient enrollment
.
At present, the clinical trial is being carried out in multiple clinical centers in Tianjin and the Guangdong-Hong Kong-Macao Greater Bay Area
.
Institute of Hematology) completed the first patient enrollment
.
At present, the clinical trial is being carried out in multiple clinical centers in Tianjin and the Guangdong-Hong Kong-Macao Greater Bay Area
.
Dr.
Wei Dong, CEO of Boya Jiyin, said that the cooperation with the Cell Ecology Haihe Laboratory will help further expand the layout and application in the field of hematopoietic stem cells.
The transformation experience in the field will bring more independent innovative treatment plans to patients in China and around the world as soon as possible
.
(Finish)
Wei Dong, CEO of Boya Jiyin, said that the cooperation with the Cell Ecology Haihe Laboratory will help further expand the layout and application in the field of hematopoietic stem cells.
The transformation experience in the field will bring more independent innovative treatment plans to patients in China and around the world as soon as possible
.
(Finish)
